Investors Buy Shares of Gilead Sciences (GILD) on Weakness

Share on StockTwits

Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Thursday. $91.35 million flowed into the stock on the tick-up and $60.09 million flowed out of the stock on the tick-down, for a money net flow of $31.26 million into the stock. Of all companies tracked, Gilead Sciences had the 31st highest net in-flow for the day. Gilead Sciences traded down ($0.60) for the day and closed at $71.88

A number of brokerages recently issued reports on GILD. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday. Mizuho set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 26th. Barclays raised their price objective on shares of Gilead Sciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 26th. Robert W. Baird lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price objective for the company. in a research note on Thursday, July 26th. Finally, Piper Jaffray Companies lowered shares of Gilead Sciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $85.00 to $75.00 in a research note on Friday, October 26th. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $87.84.

The company has a market capitalization of $93.76 billion, a P/E ratio of 8.32, a P/E/G ratio of -2.81 and a beta of 1.01. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The firm had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same period in the previous year, the business posted $2.27 earnings per share. As a group, equities analysts expect that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.20%. Gilead Sciences’s dividend payout ratio is presently 26.64%.

In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $78.04, for a total value of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at $239,408,146.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 150,000 shares of company stock valued at $11,087,500 over the last quarter. Company insiders own 1.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in Gilead Sciences during the third quarter valued at approximately $100,000. Reilly Financial Advisors LLC grew its position in Gilead Sciences by 98.3% during the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Gilead Sciences during the second quarter valued at approximately $132,000. Brand Asset Management Group Inc. bought a new stake in Gilead Sciences during the second quarter valued at approximately $139,000. Finally, TRUE Private Wealth Advisors bought a new stake in Gilead Sciences during the third quarter valued at approximately $174,000. Hedge funds and other institutional investors own 78.09% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://weekherald.com/2018/11/10/investors-buy-shares-of-gilead-sciences-gild-on-weakness.html.

Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Read More: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply